The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology
Official Title: A Non-interventional Survey on the Epidermal Growth Factor Receptor (EGFR) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology
Study ID: NCT01106781
Brief Summary: This is a descriptive observational study. The primary objective is to explore the EGFR gene mutation status in early stage NSCLC with adenocarcinoma histology after complete resection. The patients should be histological confirmed adenocarcinoma of the lung, have received complete resection and tested for EGFR mutation in regular medical practice.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Research Site, Beijing, Beijing, China
Research Site, Chongqing, Chongqing, China
Research Site, Guangzhou, Guangdong, China
Research Site, Wuhan, Hubei, China
Research Site, Nanjing, Jiangsu, China
Research Site, Suzhou, Jiangsu, China
Research Site, Changchun, Jilin, China
Research Site, Shenyang, Liaoning, China
Research Site, Qingdao, Shandong, China
Research Site, Shanghai, Shanghai, China
Research Site, Chengdu, Sichuan, China
Research Site, Tianjin, Tianjin, China
Research Site, Hangzhou, Zhejiang, China
Name: Karen Atkin
Affiliation: Astrazeneca China R&D
Role: STUDY_DIRECTOR
Name: Wu Yilong
Affiliation: Guangdong Provincial People's Hospital
Role: PRINCIPAL_INVESTIGATOR